| For: | Colwill M, Padley J, Qazi U, Mehta S, Donovan F, Alves AM, Pollok R, Patel K, Dawson P, Honap S, Poullis A. Risankizumab is effective following ustekinumab failure in Crohn’s disease: A real-world study from a tertiary center. World J Gastrointest Pharmacol Ther 2025; 16(4): 110273 [PMID: 41378066 DOI: 10.4292/wjgpt.v16.i4.110273] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v16/i4/110273.htm |
| Number | Citing Articles |
| 1 |
Manuel Barreiro‐de Acosta, Yamile Zabana, Laura Nieto‐García, Marta Poncela, Mariam Aguas, Cristina Martínez‐Cuevas, Federico Argüelles‐Arias, Marta Calvo, Carla J. Gargallo‐Puyuelo, Lucía Zabalza, Pilar Varela Trastoy, Maia M. Boscá‐Watts, Daniel Ceballos, Cristina Martínez Pascual, Francisco Rodríguez‐Moranta, María Luisa de Castro Parga, Patricia Suárez, Blau Camps, Vanesa Royo, Iria Baston‐Rey, Ruth de Francisco, Santiago García‐Lopez, María Dolores Martín‐Arranz, Fernando Bermejo, Inmaculada Alonso‐Abreu, Javier P. Gisbert, Montserrat Rivero, Beatriz Sicilia, Isabel Nicolás, Marta Teller, Ángel Ponferrada Díaz, Elena Ricart, María Algara, Paola Fradejas, Pilar Robledo, Lucía Madero, Ainara Elorza, Marta Piqueras, Mari Fe Garcia‐Sepulcre, Eva Sesé, Alejandro Hernandez‐Camba, Sandra Izquierdo, Ana M. Trapero, Eva Iglesias, María Teresa Diz‐Lois Palomares, Eduard Brunet‐Mas, Jesús Castro Poceiro, David Busquets, Miriam Manosa, Ramón Pajares, Juan A. Ferrer, Daniel Carpio, Francisco Mesonero, Luis Bujanda, Rufo Lorente, Javier Santos, Carlos Martínez Flores, Carlos González‐Muñoza, Daniel Martín, Margarita Menacho, Nuria Maroto, Martín Irabien, Sol Porto‐Silva, Eugeni Domènech, Rocío Ferreiro‐Iglesias. Real‐World Effectiveness of Risankizumab in Refractory Crohn's Disease: The RISANCROHN Study From the ENEIDA Registry. Alimentary Pharmacology & Therapeutics 2026; 64(6) doi: 10.1111/apt.70783
|
| 2 |
Thomas D Butler, Anthony Beard, Abosede Ososanya, Emma Parr, Jon Kwok, Hibest Fekadu, Faris Chater, Villa Kakosa, James Morgan, Catherine Bonnar, Karen Kemp, Emma Nixon, Andrew Kneebone, Anish Kuriakose Kuzhiyanjal, Clare Ormerod, Paul P Knight, Elinor Shuttleworth, Rhys Butcher, Kelly Chatten, Ben Crooks, Jimmy K Limdi, Katherine White. Outcomes of risankizumab use in adults with Crohn’s disease in a real-world setting (ARISE-CD): a multicentre, retrospective cohort study. BMJ Open Gastroenterology 2026; 13(1) doi: 10.1136/bmjgast-2026-002320
|
| 3 |
Hilda Hounkpatin, Benjamin Barton, Margaret Ogden, Rohini Mathur, Beth Stuart, Hajira Dambha-Miller. Understanding Remission of Long-Term Conditions Through Electronic Health Records: Scoping Review. Journal of Medical Internet Research 2026; 28 doi: 10.2196/80796
|
| 4 |
Anthony Buisson, Karim Gebara, Bénédicte Caron, Gilles Boschetti, Cyrielle Gilletta de Saint Joseph, Maria Nachury, Hedia Brixi, Pascal Juillerat, Mélanie Serrero, Lucine Vuitton, Xavier Hebuterne, Ludovic Caillo, Antoine Blain, David Laharie, Laurent Peyrin-Biroulet, Romain Altwegg, Guillaume Le Cosquer, Bruno Pereira, Mathurin Fumery. Acceptability and tolerability of risankizumab maintenance therapy administered via on-body injector in patients with Crohn’s disease: Results of the ACCEPT-OBI study. Therapeutic Advances in Gastroenterology 2026; 19 doi: 10.1177/17562848261489118
|
| 5 |
Felix Pius Omullo. Risankizumab redefines Crohn’s treatment after ustekinumab failure. World Journal of Gastrointestinal Pharmacology and Therapeutics 2026; 17(1): 114412 doi: 10.4292/wjgpt.v17.i1.114412
|